1. |
Kim JH, Kang SW, Kong MG, et al. Assessment of retinal layers and visual rehabilitation after epiretinal membrane removal[J]. Graefe's Arch Clin Exp Ophthalmol, 2013, 251(4): 1055-1064. DOI: 10.1007/s00417-012-2120-7.
|
2. |
Kim J, Rhee KM, Woo SJ, et al. Long-term temporal changes of macular thickness and visual outcome after vitrectomy for idiopathic epiretinal membrane[J]. Am J Ophthalmol, 2010, 150(5): 701-709. DOI: 10.1016/j.ajo.2010.05.037.
|
3. |
Chang YC, Lin CC, Wu WC. Long-term anatomical and functional outcome of three intravitreal bevacizumab injections for persistent macular edema after idiopathic macular epiretinal membrane peeling[J]. Ophthalmologica Extra, 2014, 1(1): 1-8. DOI: 10.1159/000360185.
|
4. |
Chatziralli I, Dimitriou E, Theodossiadis G, et al. Treatment of macular edema after pars plana vitrectomy for idiopathic epiretinal membrane using intravitreal dexamethasone implant: long-term outcomes[J]. Ophthalmologica, 2019, 242(1): 16-21. DOI: 10.1159/000496705.
|
5. |
Kim SJ, Martin DF, Hubbard GR, et al. Incidence of postvitrectomy macular edema using optical coherencetomography[J]. Ophthalmology, 2009, 116(8): 1531-1537. DOI: 10.1016/j.ophtha.2009.02.008.
|
6. |
Shaikh AH, Petersen MR, Sisk RA, et al. Comparative effectiveness of the dexamethasone intravitreal implant in vitrectomized and non-vitrectomized eyes with macular edema secondary to central retinal vein occlusion[J]. Ophthalmic Surg Lasers Imaging Retina, 2013, 44(1): 28-33. DOI: 10.3928/23258160-20121221-09.
|
7. |
Haller JA, Bandello F, Belfort RJ, et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion[J]. Ophthalmology, 2010, 117(6): 1134-1146. DOI: 10.1016/j.ophtha.2010.03.032.
|
8. |
Boyer DS, Faber D, Gupta S, et al. Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients[J]. Retina, 2011, 31(5): 915-923. DOI: 10.1097/IAE.0b013e318206d18c.
|
9. |
Pohlmann D, Vom BG, Winterhalter S, et al. Dexamethasone inserts in noninfectious uveitis: a single-center experience[J]. Ophthalmology, 2018, 125(7): 1088-1099. DOI: 10.1016/j.ophtha.2017.12.038.
|
10. |
Khurana RN, Porco TC. Efficacy and safety of dexamethasone intravitreal implant for persistent uveitic cystoid macular edema[J]. Retina, 2015, 35(8): 1640-1646. DOI: 10.1097/IAE.0000000000000515.
|
11. |
Bucolo C, Gozzo L, Longo L, et al. Long-term efficacy and safety profile of multiple injections of intravitreal dexamethasone implant to manage diabetic macular edema: a systematic review of real-world studies[J]. J Pharmacol Sci, 2018, 138(4): 219-232. DOI: 10.1016/j.jphs.2018.11.001.
|
12. |
Chang-Lin JE, Burke JA, Peng Q, et al. Pharmacokinetics of a sustained-release dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes[J]. Invest Ophthalmol Vis Sci, 2011, 52(7): 4605-4609. DOI: 10.1167/iovs.10-6387.
|
13. |
Frisina R, Pinackatt SJ, Sartore M, et al. Cystoid macular edema after pars plana vitrectomy for idiopathic epiretinal membrane[J]. Graefe's Arch Clin Exp Ophthalmol, 2015, 253(1): 47-56. DOI: 10.1007/s00417-014-2655-x.
|
14. |
Iovino C, Giannaccare G, Pellegrini M, et al. Efficacy and safety of combined vitrectomy with intravitreal dexamethasone implant for advanced stage epiretinal membrane[J]. Drug Des Devel Ther, 2019, 13: 4107-4114. DOI: 10.2147/DDDT.S229031.
|
15. |
Savastano A, Bitossi A, Giansanti F, et al. Evaluation of intraoperative slow-release dexamethasone implant combined with idiopathic epiretinal membrane removal[J]. Graefe's Arch Clin Exp Ophthalmol, 2021, 259(2): 379-385. DOI: 10.1007/s00417-020-04911-5.
|
16. |
Guidi G, Casini G, Ripandelli G, et al. Residual intrareinal edema after 25-gauge vitrectomy and macular pucker removal: intraoperative sustained-release dexamethasone a real treatment option?[J]. Retina, 2018, 38(5): 993-999. DOI: 10.1097/IAE.0000000000001627.
|
17. |
Govetto A, Lalane RR, Sarraf D, et al. Insights into epiretinal membranes: presence of ectopic inner foveal layers and a new optical coherence tomography staging scheme[J]. Am J Ophthalmol, 2017, 175: 99-113. DOI: 10.1016/j.ajo.2016.12.006.
|
18. |
Schulze-Bonsel K, Feltgen N, Burau H, et al. Visual acuities "hand motion" and "counting fingers" can be quantified with the freiburg visual acuity test[J]. Invest Ophthalmol Vis Sci, 2006, 47(3): 1236-1240. DOI: 10.1167/iovs.05-0981.
|
19. |
Suzuki T, Hayakawa K, Nakagawa Y, et al. Topical dorzolamide for macular edema in the early phase after vitrectomy and epiretinal membrane removal[J]. Clin Ophthalmol, 2013, 7: 549-553. DOI: 10.2147/OPTH.S42188.
|
20. |
Hattenbach LO, Springer-Wanner C, et al. Intravitreal sustained-release steroid implants for the treatment of macular edema following surgical removal of epiretinal membranes[J]. Ophthalmologica, 2017, 237(4): 232-237. DOI: 10.1159/000464259.
|
21. |
张红梅, 刘洪涛. 特发性黄斑前膜形成的危险因素及发生机制的研究现状[J]. 中华眼底病杂志, 2021, 37(8): 651-655. DOI: 10.3760/cma.j.cn511434-20200612-00279.Zhang HM, Liu HT. The study of the risk factors and pathogenesis of idiopathic epimacular membrane[J]. Chin J Ocul Fundus Dis, 2021, 37(8): 651-655. DOI: 10.3760/cma.j.cn511434-20200612-00279.
|
22. |
Bellocq D, Korobelnik JF, Burillon C, et al. Effectiveness and safety of dexamethasone implants for post-surgical macular oedema including Irvine-Gass syndrome: the EPISODIC study[J]. Br J Ophthalmol, 2015, 99(7): 979-983. DOI: 10.1136/bjophthalmol-2014-306159.
|
23. |
Bellocq D, Pierre-Kahn V, Matonti F, et al. Effectiveness and safety of dexamethasone implants for postsurgical macular oedema including Irvine-Gass syndrome: the EPISODIC-2 study[J]. Br J Ophthalmol, 2017, 101(3): 333-341. DOI: 10.1136/bjophthalmol-2016-308544.
|
24. |
Parisi G, Fallico M, Avitabile T, et al. Intravitreal dexamethasone implant for postoperative macular oedema secondary to vitrectomy for epiretinal membrane and retinal detachment: a systematic review and meta-analysis[J/OL]. J Ophthalmol, 2021, 2021: 6627677[2021-04-16]. https://pubmed.ncbi.nlm.nih.gov/33953965/. DOI: 10.1155/2021/6627677.
|
25. |
Chang-Lin JE, Attar M, Acheampong AA, et al. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant[J]. Invest Ophthalmol Vis Sci, 2011, 52(1): 80-86. DOI: 10.1167/iovs.10-5285.
|
26. |
Chang YC, Liu PK, Kao TE, et al. Dexamethasone intravitreal implant (Ozurdex) for long-term macular edema after epiretinal membrane peeling surgery[J/OL]. J Ophthalmol, 2018, 2018: 5832186[2018-12-10]. https://pubmed.ncbi.nlm.nih.gov/30693103/. DOI: 10.1155/2018/5832186.
|
27. |
Furino C, Boscia F, Recchimurzo N, et al. Intravitreal dexamethasone implant for refractory macular edema secondary to vitrectomy for macular pucker[J]. Retina, 2014, 34(8): 1612-1616. DOI: 10.1097/IAE.0000000000000105.
|
28. |
Sane SS, Ali MH, Kuppermann BD, et al. Comparative study of pars plana vitrectomy with or without intravitreal dexamethasone implant for idiopathic epiretinal membrane[J]. Indian J Ophthalmol, 2020, 68(6): 1103-1107. DOI: 10.4103/ijo.IJO_1045_19.
|